Silodosin — Discount Pricing

Other medications in Urology

• Solifenacin
• Tadalafil
• Tadalafil (BPH)
• Tamsulosin
• Terazosin
• Tolterodine
• Vardenafil
• Vibegron

About Silodosin

If you're experiencing symptoms of an enlarged prostate, known as Benign Prostatic Hyperplasia (BPH), your doctor might prescribe silodosin. This medication helps improve urinary flow and reduce discomfort. At TheDrugClub, we understand the importance of affordable healthcare. Learn more about silodosin and how our membership can help you save on your prescription costs.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Silodosin is approved for (FDA label)

Silodosin capsule, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see CLINICAL STUDIES (14) ]. Silodosin capsule is not indicated for the treatment of hypertension. Silodosin capsule, an alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Silodosin capsule is not indicated for the treatment of hypertension. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 18, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Silodosin (FDA label)

The 8 mg capsules are white to off white colored powder filled in size “1” hard gelatin capsules with white opaque body imprinted with “8 mg” and white opaque cap imprinted “S” with black ink. The 4 mg capsules are white to off white colored powder filled in size “3” hard gelatin capsules with white opaque body imprinted with “4 mg” and white opaque cap imprinted “S” with black ink. Capsules: 8 mg and 4 mg. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: ee8d577e-948d-4164-9671-c876544ac83b. SPL document ID: 43e34468-1d75-4953-92c8-fbaae64f7ce3. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Silodosin (FDA label)

Most common adverse reactions (incidence > 2%) are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis, and nasal congestion. ( 6) To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In U.S. clinical trials, 897 patients with BPH were exposed to 8 mg silodosin daily. This includes 486 patients exposed for 6 months and 168 patients exposed for 1 year.

Source: FDA prescribing information (DailyMed). Set ID: ee8d577e-948d-4164-9671-c876544ac83b. SPL document ID: 43e34468-1d75-4953-92c8-fbaae64f7ce3. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Silodosin (FDA label)

Severe renal impairment (CCr < 30 mL/min) Severe hepatic impairment (Child-Pugh score ≥ 10) Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) [see DRUG INTERACTIONS (7.1) ] Patients with a history of hypersensitivity to silodosin or any of the ingredients of silodosin [see ADVERSE REACTIONS (6.2) and DESCRIPTION (11) ] Patients with severe renal impairment [Creatinine Clearance (CCr < 30 mL/min)]. ( 4 ) Patients with severe hepatic impairment (Child-Pugh score >10). ( 4 ) Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir).( 4 ) Patients with a history of hypersensitivity to silodosin or any of the ingredients of silodosin.( 4 )

Source: FDA prescribing information (DailyMed). Set ID: ee8d577e-948d-4164-9671-c876544ac83b. SPL document ID: 43e34468-1d75-4953-92c8-fbaae64f7ce3. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Silodosin (FDA label)

Postural hypotension, with or without symptoms (e.g., dizziness), may develop when beginning silodosin treatment. ( 5.1 ) In patients with moderate renal impairment, silodosin dose should be reduced to 4 mg once daily. ( 5.2 ) Silodosin should not be used in combination with other alpha-blockers.( 5.5 ) Examine patients thought to have BPH prior to starting therapy with silodosin to rule out the presence of carcinoma of the prostate. ( 5.6 ) Inform patients planning cataract surgery to notify their ophthalmologist that they are taking silodosin because of the possibility of Intraoperative Floppy Iris Syndrome (IFIS). ( 5.7 ) 5.1 Orthostatic Effects Postural hypotension, with or without symptoms (e.g., dizziness) may develop when beginning silodosin treatment. As with other alpha-blockers, there is potential for syncope.

Source: FDA prescribing information (DailyMed). Set ID: ee8d577e-948d-4164-9671-c876544ac83b. SPL document ID: 43e34468-1d75-4953-92c8-fbaae64f7ce3. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Silodosin (FDA label)

Strong P-glycoprotein inhibitors (e.g., cyclosporine): Co-administration may increase plasma silodosin concentration. Concomitant use is not recommended. ( 7.2 ) Alpha-blockers: Interactions involving concomitant use have not been determined. However, interactions are expected and concomitant use is not recommended. ( 7.3 ) Concomitant use of PDE5 inhibitors with alpha-blockers including silodosin can potentially cause symptomatic hypotension. ( 5.5 ) ( 7.5 ) 7.1 Moderate and Strong CYP3A4 Inhibitors In a clinical metabolic inhibition study, a 3.8-fold increase in silodosin maximum plasma concentrations and 3.2-fold increase in silodosin exposure were observed with concurrent administration of a strong CYP3A4 inhibitor, 400 mg ketoconazole. Use of strong CYP3A4 inhibitors such as itraconazole or ritonavir may cause plasma concentrations of silodosin to increase.

Source: FDA prescribing information (DailyMed). Set ID: ee8d577e-948d-4164-9671-c876544ac83b. SPL document ID: 43e34468-1d75-4953-92c8-fbaae64f7ce3. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.